HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $139
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $119 to $139.
May 22, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Krystal Biotech and raises the price target from $119 to $139.
The news of HC Wainwright & Co. maintaining a Buy rating and raising the price target for Krystal Biotech is positive for the company's stock. This indicates that the analyst has a positive outlook on the company's performance and growth potential, which could lead to an increase in investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100